Folic acid and human malformations: A summary and evaluation

Reproductive Toxicology

Volumn 14, Issue 5, 2000, Pages 463-476

  Kalter, Harold ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPTERIN; ANTIMETABOLITE; FOLIC ACID; FOLIC ACID ANTAGONIST;

ADULT; ANIMAL TISSUE; ARTICLE; BIRTH DEFECT; CONGENITAL MALFORMATION; DIET SUPPLEMENTATION; EMBRYO; FEMALE; FOLIC ACID DEFICIENCY; HUMAN; HUMAN TISSUE; NEURAL TUBE DEFECT; NONHUMAN; PREGNANCY; PRENATAL DIAGNOSIS; SPONTANEOUS ABORTION; TERATOGENICITY; VITAMIN INTAKE;

ABNORMALITIES; ABNORMALITIES, DRUG-INDUCED; ADULT; FEMALE; FOLIC ACID; FOLIC ACID ANTAGONISTS; FOLIC ACID DEFICIENCY; HUMANS; NEURAL TUBE DEFECTS; PREGNANCY;

ANIMALIA;

EID: 0033745160     PISSN: 08906238     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0890-6238(00)00093-9     Document Type: Article

References (174)

1. Pteroylglutamic acid and reproduction in the rat
2. Effects of 4-amino-pteroylglutamic acid (aminopterin) on early pregnancy
3. Therapeutic abortions with a folic acid antagonist, 4-aminopteroylglutamic acid (4-amino P.G.A.) administered by the oral route
4. Clinical teratology counseling and consultation case report: Low dose methotrexate exposure in the early weeks of pregnancy
5. Developmental delay in fetal aminopterin/methotrexate syndrome
6. Aminopterin and methotrexate: Folic acid deficiency
7. Methotrexate compared with mercaptopurine for early induced abortion
8. Teratological and reproductive studies in non-human primates
9. Infants of mothers with megaloblastic anemia due to folate deficiency
10. Megaloblastic anemia in pregnancy and the puerperium
11. Folic acid and reproduction
12. Folic acid metabolism and human embryopathy
13. Obstetric and fetal complications in folate-deficient adolescent girls
14. Pathogenesis of spina bifida
15. Maternal folate deficiency and pregnancy wastage. II. Fetal malformation
16. Folic acid deficiency and congenital malformations
17. Folates and the fetus
18. 12 concentrations in pregnancies associated with neural tube defects
19. Maternal vitamin levels during pregnancies producing infants with neural tube defects
20. Investigation of factors influencing folate status in women who have had a neural tube defect-affected child
21. The effect of periconceptional supplementation on blood folate vitamin concentration in women at risk for neural tube defect
22. Is disordered folate metabolism the basis for the genetic predisposition to neural tube defects?
23. Folate levels and neural tube defects: Implications for prevention
24. Prevalence of neural tube defects in 20 regions of Europe and the impact of prenatal diagnosis, 1980-1986
25. Neural tube defects in the British Isles EUROCAT centres, 1980-1992
26. 12 are independent risk factors for neural tube defects
27. 12 and transcobalamins in neural tube defects
28. 12, calcium, and lead levels associated with neural tube defects
29. Vitamins to prevent neural tube defects
30. Folic acid and the prevention of neural tube defects
31. Major central nervous system malformations in South Wales. I. Incidence, local variations, and geographical factors
32. Major central nervous system malformations in South Wales. II. Pregnancy factors, seasonal variation, and social class effects
33. Epidemiology of neural tube defects
34. Social class and foetal mortality
35. Congenital malformations of the central nervous system in Scotland
36. Evidence for an environmental aetiology for anencephalus
37. Vitamin deficiencies and neural tube defects
38. Apparent prevent of neural tube defects by periconceptional vitamin supplementation
39. Periconceptional vitamin supplementation and the prevention of neural tube defects in southeast England and Northern Ireland
40. Iniencephalus
41. Iniencephaly and anencephaly with spinal retroflexion: A comparative study of eight human specimens
42. Congenital abnormalities at birth: Their association in the same patient
43. Possible prevention of neural-tube defects by periconceptional vitamin supplementation
44. Possible prevention of neural-tube defects by periconceptional vitamin supplementation
45. Recurrence rates for neural tube defects and vitamin supplementation
46. Influence of social class on the risk of recurrence of anencephalus and spina bifida
47. Further experience of vitamin supplementation for prevention of neural tube defect recurrences
48. Vitamin supplementation and neural tube defects
49. Vitamin supplementation and neural tube defects
50. Vitamins and neural tube defects
51. Neural-tube defects and vitamins: The need for a randomized clinical trial
52. Prevention of neural tube defect recurrences in Yorkshire: Final report
53. Double-blind randomised controlled trial of folate treatment before conception to prevent recurrence of neural tube defects
54. Primary prevention of neural tube defects with folic acid supplementation: Cuban experience
55. Prevention of neural tube defects: Results of the Medical Research Council Vitamin Study
56. Ethics of a randomized trial of periconceptual vitamins
57. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation
58. Prevention of congenital abnormalities by periconceptional multivitamin supplementation
59. Population-based case control study of folic acid supplementation during pregnancy
60. Folic acid to prevent neural tube defects
61. Epidemiological studies of congenital abnormalities in Hungary
62. A randomised trial of low dose folic acid to prevent neural tube defects
63. Neural tube defect surveillance and folic acid intervention-Texas-Mexico border, 1993-1998
64. Periconceptional use of multivitamins and the occurrence of neural tube defects
65. What kind of controls to use in case control studies of malformed infants: Recall bias versus 'teratogen nonspecificity' bias
66. The frequency of birth defects
67. Comparative incidence of birth defects in Negro and White children
68. Racial variations in the incidence of congenital malformations
69. Does taking vitamins at the time of conception prevent neural tube defects?
70. Declining incidence of central nervous system anomalies in New York State
71. Completeness and accuracy of reporting of malformations on birth certificates
72. Bias in congenital malformations information from the birth certificate
73. Vietnam Veterans' Risk for Fathering Babies with Birth Defects
74. Five-decade international trends in the relation of perinatal mortality and congenital malformations: Stillbirth and neonatal death compared
75. The absence of a relation between the periconceptional use of vitamins and neural-tube defects
76. Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects
77. Vitamins during pregnancy and neural tube defects
78. Vitamins during pregnancy and neural tube defects
79. Vitamins during pregnancy and neural tube defects
80. Periconceptional use of multivitamins and the prevalence of neural-tube defects
81. Vitamins during pregnancy and neural tube defects
82. Dietary folate as a risk factor for neural-tube defects: Evidence from a case-control study in Western Australia
83. Periconceptional vitamin supplementation and neural-tube defects: Evidence from a case-control study in Western Australia and a review of recent publications
84. Pregnancy outcomes in a randomised controlled trial of perconceptional multivitamin supplementation: Final report
85. Periconceptional folic acid exposure and risk of neural tube defects
86. Case-control study of vitamin supplementation and neural tube defects: Consideration of potential confounding by lifestyle factors
87. Unrecognised epidemic of anencephaly and spina bifida
88. Periconceptional vitamin use, dietary folate, and the occurrence of neural tube defects
89. Risk for neural tube defect-affected pregnancies among women of Mexican descent and white women in California
90. Neural tube defect prevalence in California (1990-1994); elicing patterns by type of defect and maternal race/ethnicity
91. Neural tube defects along the Texas-Mexico border, 1993-1995
92. Collecting and interpreting birth defects surveillance data by Hispanic ethnicity: A comparative study
93. Congenital malformations, especially anencephalus, in Taiwan
94. Congenital malformations: A report of a study of series of consecutive births in 24 centres
95. The incidence of congenital malformations in a Chinese population: The Taipei collaborative study
96. Neural-tube defects in Hang Kong Chinese
97. Ethnic variables in perinatal mortality rates
98. Neural tube defects in Beijing-Tianjin area of China: Urban-rural distribution and some epidemiological characteristics
99. Elevated rates of severe neural tube defects in a high-prevalence area in northern China
100. Central nervous system congenital malformations, especially neural tube defects in 29 provinces, metropolitan cities and autonomous regions of China: Chinese Birth Defects Monitoring system
101. Prevention of neural-tube defects with folic acid in China
102. Neural tube defects, methylenetetrahydofolate reductase mutation, and north/south dietary differences in China
103. The changing epidemiology of neural tube defects: United States, 1968-1989
104. Recommendations for the use of folic acid to reduce the numbers of cases of spina bifida and other neural tube defects
105. Use of folic acid for prevention of spina bifida and other neural tube defects
106. Proposals for folic acid fortification and labeling of certain foods to reduce risks of neural tube defects
107. Folic acid and the prevention of neural tube defects
108. Comparison of national policies on periconceptional use of folic acid to prevent spina bifida and anencephaly (SBA)
109. Folate supplements and neural tube defects
110. Folic acid-preventable spina bifida and anencephaly
111. Prevention of folic acid-preventable spina bifida and anencephaly
112. Minimum effective dose of folic acid for food fortification to prevent neural-tube defects
113. Folic acid fortification to prevent neural tube defects
114. Food standards: Amendment of the standards of identity for enriched grain products to require addition of folic acid
115. The effect of folic acid fortification on plasma folate and total homocysteine concentrations
116. Trends in serum folate after food fortification
117. Has advice on periconceptional folate supplmentation reduced neural-tube defects?
118. Neural tube defects and periconceptional folic acid in England and Wales: Retrospective study
119. Folic acid fortification
120. Vital record incidence of congenital malformations in New York State
121. Epidemics of anencephalus and spina bifida in Ireland since 1900
122. Epidemic waves in the prevalence of anencephaly and spina bifida in New York State
123. Time trends of spina bifida in Sweden 1947-81
124. Analysis of the changing birth prevalence of neural tube defects in Hungary
125. The declining prevalence of anencephalus and spina bifida: Its nature, causes, and implications
126. Epidemiology of stillbirths and infant deaths due to congenital malformations
127. Intergenerational factors in the etiology of anencephalus and spina bifida
128. Phenotypic expression of lethal chromosomal anomalies in human abortuses
129. Normal and abnormal development of human embryos: First report of the analysis of 1,213 intact embryos
130. Terathanasia
131. Area differences in spontaneous abortion rates in South Wales and their relation to neural tube defect incidence
132. Area differences in the incidence of neural tube defect and the rate of spontaneous abortion
133. Neural tube defects in spontaneous abortions
134. Fetal loss
135. Can terathansia explain the protective effect of folic-acid supplementation on birth defects?
136. Terathanasia, folic acid, and birth defects
137. Terathanasia, folic acid, and birth defects
138. Terathanasia, folic acid, and birth defects
139. Folic acid and prevention of neural-tube defects
140. Miscarriage and the use of multi-vitamins or folic acid
141. Alpha-fetoprotein in the antenatal diagnosis of anencephaly and spina bifida
142. Prenatal diagnosis of spina bifida and anencephaly by maternal serum-α-fetoprotein: A controlled study
143. Ultrasound visualization of congenital malformations
144. Spina bifida and anencephaly: Fewer patients, more problems
145. Prevention of neural tube defects in an urban health district
146. 19-Year incidence of neural tube defects in an area under constant surveillance
147. The impact of maternal serum alpha fetoprotein screening on open neural tube defect births in north-east Scotland
148. Screening for congenital neural tube defects in a high-risk area: An epidemiological perspective
149. The impact of maternal serum alphafetoprotein screening on the birth prevalence of neural tube defects in Manitoba: 1979-1990
150. Prevalence of neural tube defects in the Province of Quebec, 1992
151. Anencephaly: Changes in prenatal detection and birth status, 1972 through 1990
152. Impact of prenatal diagnosis on the birth prevalence of neural tube defects, Atlanta, 1990-1991
153. Surveillance for anencephaly and spina bifida and the impact of prenatal diagnosis-United States, 1985-1994
154. Impact of prenatal diagnosis and elective termination on prevalence and risk estimates of neural tube defects in California, 1989-1991
155. Impact of prenatal diagnosis and elective termination on the prevalence of selected birth defects in Hawaii
156. The impact of screening for open neural tube defects in England and Wales
157. Prenatal screening for open neural-tube defects in Maine
158. Prevalence of neural tube defects in South Australia, 1961-1991: Effectiveness and impact of prenatal diagnosis
159. Prevalence of neural tube defects in northeastern France, 1979-1994: Impact of prenatal diagnosis
160. Periconceptional supplementation with vitamins and folic acid to prevent recurrence of cleft lip
161. Case-control study of periconceptional folic acid supplementation and oral clefts
162. Dose-dependent effect of folic acid on the prevention of orofacial defects
163. Multivitamin supplementation and risk of birth defects
164. Role of amniotic fluid homocysteine level and of fetal 5,10-methylenetetrahydrofolate reductase genotype in the etiology of neural tube defects
165. Socioeconomic inequalities in risk of congenital anomaly